pralidoxime

Absorption: IV administration results in complete bioavailability.

Distribution: Widely distributed throughout extracellular water. Does not appear to enter the CNS.

Metabolism/Excretion: 80–90% excreted unchanged by the kidneys.

Half-Life: 0.8–2.7 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
IM	unknown	10–20 min	unknown
IV	unknown	5–15 min	unknown

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Hypersensitivity.

Use Cautiously in:

Myasthenia gravis (may precipitate myasthenic crisis);
Renal impairment (dose ↓ required);
Efficacy in carbamate insecticide poisoning is not known (may ↑ toxicity);
OB: Safety not established in pregnancy; use during pregnancy only if clearly needed;
Lactation: Safety not established in breastfeeding; use while breastfeeding only if clearly needed.

Adv. Reactions/Side Effects ⬆ ⬇

CV: tachycardia

Derm: rash

EENT: blurred vision, diplopia, impaired accommodation

GI: nausea

Local: pain at injection site

MS: muscle rigidity, muscle weakness

Neuro: dizziness, drowsiness, headache

Resp: hyperventilation, LARYNGOSPASM

Interactions ⬆ ⬇

Drug-drug:

Avoid concurrent use with succinylcholine, morphine, aminophylline, theophylline, and respiratory depressants, including barbiturates, opioid analgesics, and sedative/hypnotics, in patients with anticholinesterase poisoning.

Route/Dosage ⬆ ⬇

IV route is preferred. In organophosphate poisoning, atropine 2–4 mg IV is given concurrently after hypoxemia is improved. Atropine is repeated every 5–10 min until toxicity is encountered and is then continued for at least 48 hr

Organophosphate Poisoning

IV (Adults ): 1–2 g; may be repeated in 1 hr if muscle paralysis is still present. Additional doses may be given every 10–12 hr if muscle weakness persists. IV route is preferred; if not available, may be given IM or SUBQ.
IM (Adults and Children ≤16 yr and ≥40 kg): Mild symptoms: 600 mg; if mild symptoms persist after 15 min, given another 600 mg; if mild symptoms persist after 15 min, given another 600 mg; if symptoms continue to persist after 1 hr of last 600-mg dose, may repeat dosing regimen of three 600-mg doses given 15 min apart; Severe symptoms: Administer three 600-mg doses in rapid succession (total of 1800 mg); if symptoms continue to persist after 1 hr of last 600-mg dose, may repeat dosing regimen of three 600-mg doses given in rapid succession.
IV (Children ≤16 yr): Give loading dose of 20–50 mg/kg over 15–30 min; after loading dose, may give another dose of 20–50 mg/kg over 15–30 min in 1 hr if muscle paralysis is still present (can repeat dose every 10–12 hr as needed) or initiate continuous infusion of 10–20 mg/kg/hr. IV route is preferred; if not available, may be given IM or SUBQ.
IM (Children ≤16 yr and <40 kg): Mild symptoms: 15 mg/kg; if mild symptoms persist after 15 min, given another 15 mg/kg; if mild symptoms persist after 15 min, given another 15 mg/kg; if symptoms continue to persist after 1 hr of last 15 mg/kg dose, may repeat dosing regimen of three 15 mg/kg doses given 15 min apart; Severe symptoms: Administer three 15 mg/kg doses in rapid succession; if symptoms continue to persist after 1 hr of last 15 mg/kg dose, may repeat dosing regimen of three 15 mg/kg doses given in rapid succession.

Anticholinesterase Overdose

IV (Adults ): 1–2 g, followed by increments of 250 mg every 5 min as needed.

Availability ⬆ ⬇

(Generic available)

Powder for injection: 1 g/vial

Assessment ⬆ ⬇

Determine type of insecticide and time of patient’s exposure. Therapy should begin as soon as possible within 24 hr. Contact poison control center for complete information on the specific insecticide.
Monitor neuromuscular status before and periodically throughout therapy. Document skeletal muscle strength, tidal volume, and vital capacity. Note presence of nicotinic effects of anticholinesterases (twitching, muscle cramps, fasciculations, weakness, pallor, tachycardia, increased BP).
Closely monitor respirations, pulse, and BP. Rapid IV infusion rate may cause tachycardia, laryngospasm, muscle rigidity, and hypertension. If hypertension occurs, infusion rate may be decreased or infusion discontinued. Phentolamine may be required to control BP.

Lab Test Considerations:

May cause ↑ AST, ALT, and CK levels. These usually return to normal in 2 wk.

Implementation ⬆ ⬇

Do not confuse pralidoxime with pyridoxine.
Concurrent atropine and supportive measures (suctioning, intubation, and ventilation) may be ordered. Atropine 2–6 mg IV in adults (50–100 mcg/kg in children) is given concurrently. If patient is cyanotic, give atropine IM while improving ventilatory status. Atropine is repeated every 5–60 min until toxicity is encountered and is then continued for at least 48 hr. Atropine is used to reverse muscarinic effects (bronchoconstriction, dyspnea, cough, increased bronchial secretions, nausea, vomiting, abdominal cramps, diarrhea, increased sweating, salivation, lacrimation, bradycardia, decreased BP, miosis, blurred vision, urinary frequency, incontinence) of anticholinesterases. Pralidoxime is effective only against nicotinic effects.
- Dose may need to be repeated every 3–8 hr if insecticide was ingested; absorption from bowel may continue.
- Emergency kit containing pralidoxime, sterile water for injection, 20-mL syringe, needle, and alcohol swab is commercially available for SUBQ, IM, or IV injection.
- If dermal exposure has occurred, remove clothing and thoroughly wash hair and skin first in sodium bicarbonate, then with alcohol as soon as possible. Health care workers should wear gloves to prevent self-exposure. Carefully dispose of clothing to prevent contamination of others.
IM: SC: May be administered IM or SUBQ in patients unable to tolerate IV infusion. Reconstitute by adding 3.3 mL of sterile water for injection to the 1000-mg vial for a concentration of 300 mg/mL. Do not administer solutions that are discolored or contain particulate matter.

IV Administration:

IV Push: Diluent: Reconstitute vial containing 1 g of powdered pralidoxime with 20 mL of sterile water for injection. May be administered without further dilution to patients who cannot tolerate IV infusion (for example, pulmonary edema).Concentration: Concentration will be 50 mg/mL. .
Rate: Administer over at least 5 min; not to exceed 200 mg/min.
Intermittent Infusion: Diluent: Dilute reconstituted pralidoxime in 100 mL of 0.9% NaCl.
Rate: Infuse over 15–30 min.

Patient/Family Teaching ⬆ ⬇

Explain purpose of medication to patient.

Evaluation/Desired Outcomes ⬆ ⬇

Reversal of respiratory and skeletal muscle weakness caused by exposure to organophosphate anticholinesterase insecticides or anticholinesterase overdose.

US Brand Names ⬆ ⬇

Code ⬆

NDC Code

11704- Meridian Medical Technologies, Inc.
- 11704-251- Pralidoxime Chloride
  - 11704-251-01- 1 SYRINGE, GLASS in 1 POUCH (11704-251-01) > 2 mL in 1 SYRINGE, GLASS

60977- Baxter Healthcare Corporation
- 60977-141- Protopam Chloride
  - 60977-141-01- 6 VIAL, SINGLE-DOSE in 1 PACKAGE (60977-141-01) > 20 mL in 1 VIAL, SINGLE-DOSE (60977-141-27)

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇